Updated on 2024/07/03

写真a

 
HIRUMA Kaede
 
Organization
University Medical and Dental Hospital Urology Assistant Professor
Title
Assistant Professor
External link

Research History

  • Niigata University   Urology, University Medical and Dental Hospital   Assistant Professor

    2021.9

 

Papers

  • 高リスク前立腺癌患者のRARPとHDR-BTの治療成績の比較検討

    石崎 文雄, 押金 智哉, 村田 雅樹, 晝間 楓, 鳥羽 智貴, 武田 啓介, 安樂 力, 田崎 正行, 山名 一寿, 星井 達彦, 笠原 隆, 小原 健司, 西山 勉, 海津 元樹, 冨田 善彦

    日本癌治療学会学術集会抄録集   61回   P27 - 4   2023.10

    　More details

    Language：English   Publisher：(一社)日本癌治療学会  

    researchmap

  • MicroRNAs as Potential Regulators of GSK-3β in Renal Cell Carcinoma. International journal

    Masaki Murata, Vladimir Bilim, Yuko Shirono, Akira Kazama, Kaede Hiruma, Masayuki Tasaki, Yoshihiko Tomita

    Current issues in molecular biology   45 ( 9 )   7432 - 7448   2023.9

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    The prognosis of patients with advanced renal cell carcinoma (RCC) has improved with newer therapies, including molecular-targeted therapies and immuno-oncology agents. Despite these therapeutic advances, many patients with metastatic disease remain uncured. Inhibition of glycogen synthase kinase-3β (GSK-3β) is a promising new therapeutic strategy for RCC; however, the precise regulatory mechanism has not yet been fully elucidated. MicroRNAs (miRNAs) act as post-translational regulators of target genes, and we investigated the potential regulation of miRNAs on GSK-3β in RCC. We selected nine candidate miRNAs from three databases that could potentially regulate GSK-3β. Among these, hsa-miR-4465 (miR-4465) was downregulated in RCC cell lines and renal cancer tissues. Furthermore, luciferase assays revealed that miR-4465 directly interacted with the 3' untranslated region of GSK-3β, and Western blot analysis showed that overexpression of miR-4465 significantly decreased GSK-3β protein expression. Functional assays showed that miR-4465 overexpression significantly suppressed cell invasion of A498 and Caki-1 cells; however, cell proliferation and migration were suppressed only in Caki-1 and A498 cells, respectively, with no effect on cell cycle and apoptosis. In conclusion, miR-4465 regulates GSK-3β expression but does not consistently affect RCC cell function as a single molecule. Further comprehensive investigation of regulatory networks is required in this field.

    DOI： 10.3390/cimb45090470

    PubMed

    researchmap

  • 進行性腎細胞癌に対するNivolumab単剤療法の有害事象と予後の検討

    晝間 楓, 村田 雅樹, 風間 明, 田崎 正行, 山名 一寿, 冨田 善彦

    腎癌研究会会報   ( 53 )   104 - 104   2023.7

    　More details

    Language：Japanese   Publisher：(一社)腎癌研究会  

    researchmap

  • 腎癌に対するIO治療後の腫瘍切除術に関する検討

    田崎 正行, 大橋 瑠子, 風間 明, 晝間 楓, 石崎 文雄, 丸山 亮, 山名 一寿, 冨田 善彦

    腎癌研究会会報   ( 53 )   47 - 47   2023.7

    　More details

    Language：Japanese   Publisher：(一社)腎癌研究会  

    researchmap

  • Targeting Pro-Survival Autophagy Enhanced GSK-3β Inhibition-Induced Apoptosis and Retarded Proliferation in Bladder Cancer Cells. International journal

    Yuko Shirono, Vladimir Bilim, Tsutomu Anraku, Hiroo Kuroki, Akira Kazama, Masaki Murata, Kaede Hiruma, Yoshihiko Tomita

    Current oncology (Toronto, Ont.)   30 ( 6 )   5350 - 5365   2023.5

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    Advanced bladder cancer (BC) (local invasive and/or metastatic) is not curable even with cytotoxic chemotherapy, immune checkpoint inhibitors, and targeted treatment. Targeting GSK-3β is a promising novel approach in advanced BC. The induction of autophagy is a mechanism of secondary resistance to various anticancer treatments. Our objectives are to investigate the synergistic effects of GSK-3β in combination with autophagy inhibitors to evade GSK-3β drug resistance. Small molecule GSK-3β inhibitors and GSK-3β knockdown using siRNA promote the expression of autophagy-related proteins. We further investigated that GSK-3β inhibition induced the nucleus translocation of transcription factor EB (TFEB). Compared to the GSK-3β inhibition alone, its combination with chloroquine (an autophagy inhibitor) significantly reduced BC cell growth. These results suggest that targeting autophagy potentiates GSK-3β inhibition-induced apoptosis and retarded proliferation in BC cells.

    DOI： 10.3390/curroncol30060406

    PubMed

    researchmap

  • 進行腎細胞癌に対するニボルマブおよびイピリムマブ併用療法の使用経験(Experience of treatment with nivolumab plus ipilimumab therapy(NIVO+IPI) for advanced renal cell carcinoma)

    晝間 楓, 村田 雅樹, 風間 明, 田崎 正行, 山名 一寿, 冨田 善彦

    日本泌尿器科学会総会   110回   PP67 - 05   2023.4

    　More details

    Language：English   Publisher：(一社)日本泌尿器科学会総会事務局  

    researchmap

  • Tumor-infiltrating immune cell status predicts successful response to immune checkpoint inhibitors in renal cell carcinoma. International journal

    Akira Kazama, Vladimir Bilim, Masayuki Tasaki, Tsutomu Anraku, Hiroo Kuroki, Yuko Shirono, Masaki Murata, Kaede Hiruma, Yoshihiko Tomita

    Scientific reports   12 ( 1 )   20386 - 20386   2022.11

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    Immune checkpoint inhibitors (ICI) have dramatically changed the treatment of metastatic renal cell carcinoma (mRCC). Although many studies have reported biomarkers as predicting the efficacy of ICI in mRCC, they remain controversial and have challenges to apply in real-world practice. We evaluated prognostic significance of multiple molecules associated with tumor immunity in patients treated with ICI. The molecules were detected in tumor tissues by immunohistochemical staining. We identified CD8-positive T cells and CD68-positive macrophages infiltrating into the tumor tissue as significant favorable prognostic factors for ICI treatment. Conversely, high expression of CD4-positive T cells was associated with poor response to ICI. Furthermore, we demonstrated that scoring for the expression status of these three molecules provides a remarkably accurate biomarker in patients with mRCC. Even the classical approach of immunohistochemistry could predict the outcome of ICI treatment by assessing the combined status of tumor-infiltrating immune cells.

    DOI： 10.1038/s41598-022-24437-6

    PubMed

    researchmap

  • Advanced Bladder Cancer: Changing the Treatment Landscape. International journal

    Vladimir Bilim, Hiroo Kuroki, Yuko Shirono, Masaki Murata, Kaede Hiruma, Yoshihiko Tomita

    Journal of personalized medicine   12 ( 10 )   2022.10

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    Bladder cancer is the 10th most common cancer type in the world. There were more than 573,000 new cases of bladder cancer in 2020. It is the 13th most common cause of cancer death with an estimated more than 212,000 deaths worldwide. Low-grade non-muscle-invasive bladder cancer (NMIBC) is usually successfully managed with transurethral resection (TUR) and overall survival for NMIBC reaches 90% according to some reports. However, long-term survival for muscle-invasive bladder cancer (MIBC) and metastatic bladder cancer remains low. Treatment options for bladder cancer have undergone a rapid change in recent years. Immune checkpoint inhibitors (ICI), targeted therapies, and antibody-drug conjugates are available now. As bladder cancer is genetically heterogeneous, the optimization of patient selection to identify those most likely to benefit from a specific therapy is an urgent issue in the treatment of patients with bladder cancer.

    DOI： 10.3390/jpm12101745

    PubMed

    researchmap

  • IHC免疫プロファイリングによる腎癌に対するIO-drugのバイオマーカーの同定

    風間 明, ビリーム・ウラジミル, 村田 雅樹, 晝間 楓, 黒木 大生, 白野 侑子, 安楽 力, 田崎 正行, 冨田 善彦

    日本癌治療学会学術集会抄録集   60回   O4 - 6   2022.10

    　More details

    Language：English   Publisher：(一社)日本癌治療学会  

    researchmap

  • Ulcerative interstitial cystitis in an adolescent successfully treated with complete transurethral ulcer resection: A case report. International journal

    Eri Yuki, Kenji Obara, Hiroo Kuroki, Hiroyuki Yamazaki, Kazutoshi Yamana, Akira Tadokoro, Kaede Hiruma, Yoshihiko Tomita

    IJU case reports   2 ( 1 )   51 - 53   2019.1

    　More details

    Language：English  

    Introduction: Interstitial cystitis is difficult to treat and may affect adolescents. Case presentation: A 15-year-old girl presented with severe pain upon terminal micturition that persisted for approximately 2 hours. The pain had been present for more than 1 month. Cystoscopy revealed severe erosion throughout the trigone. Transurethral fulguration did not improve her symptoms. However, complete electric resection of the ulcer markedly reduced the symptom. After complete resection, pain on urination disappeared and she has had no pain without medication for 15 months. Conclusion: Complete resection not fulguration of the ulcer is effective for interstitial cystitis in adolescent female patients.

    DOI： 10.1002/iju5.12038

    PubMed

    researchmap

▶ display all

MISC

  • 腎癌に対するIO治療後の腫瘍切除術に関する検討

    田崎 正行, 大橋 瑠子, 風間 明, 晝間 楓, 石崎 文雄, 丸山 亮, 山名 一寿, 冨田 善彦

    腎癌研究会会報   ( 53 )   47 - 47   2023.7

    　More details

    Language：Japanese   Publisher：(一社)腎癌研究会  

    researchmap

  • 新潟大学におけるカボザンチニブ+ニボルマブ併用療法の使用経験

    晝間 楓, 田崎 正行, 山名 一寿, 冨田 善彦

    腎癌研究会会報   ( 53 )   56 - 56   2023.7

    　More details

    Language：Japanese   Publisher：(一社)腎癌研究会  

    researchmap

  • 進行性腎細胞癌に対するNivolumab単剤療法の有害事象と予後の検討

    晝間 楓, 村田 雅樹, 風間 明, 田崎 正行, 山名 一寿, 冨田 善彦

    腎癌研究会会報   ( 53 )   104 - 104   2023.7

    　More details

    Language：Japanese   Publisher：(一社)腎癌研究会  

    researchmap

  • 進行性腎細胞癌に対するNivolumab単剤療法の有害事象と予後の検討

    晝間 楓, 村田 雅樹, 風間 明, 田崎 正行, 山名 一寿, 冨田 善彦

    腎癌研究会会報   ( 52 )   51 - 51   2022.7

    　More details

    Language：Japanese   Publisher：(一社)腎癌研究会  

    researchmap

  • パゾパニブ投与中に間質性肺炎を発症した2症例と当院でのパゾパニブ使用症例の検討

    村田 雅樹, 晝間 楓, 池田 正博, 田崎 正行, 山名 一寿, 齋藤 和英, 冨田 善彦

    泌尿器外科   35 ( 臨増 )   814 - 814   2022.7

    　More details

    Language：Japanese   Publisher：医学図書出版(株)  

    researchmap

  • Usefulness of inflammatory marker PNI in predicting prognosis of renal cell carcinoma undergoing nephrectomy

    鈴木一也, 晝間楓, 晝間楓, 米山健志

    日本泌尿器科学会総会(Web)   108th   1607 - 1607   2020

    　More details

    Language：Japanese  

    J-GLOBAL

    researchmap

  • Treatment outcome of Abiraterone at Nagaoka Chuo General Hospital

    28 ( 1 )   45 - 47   2019

    　More details

  • 過剰腎に生じた腎細胞癌の1例

    晝間楓, 信下智広, 高橋英祐, 照沼正博, 五十嵐俊彦

    日本泌尿器科学会総会(Web)   107th   PP1 - 199   2019

    　More details

    Language：Japanese   Publisher：(一社)日本泌尿器科学会総会事務局  

    J-GLOBAL

    researchmap

  • 当院における去勢抵抗性前立腺癌に対するアビラテロンの使用成績

    晝間楓, 信下智広, 高橋英祐, 照沼正博

    日本泌尿器科学会東部総会プログラム・抄録集   83rd ( 臨増 )   763 - 763   2018

    　More details

    Language：Japanese   Publisher：医学図書出版(株)  

    J-GLOBAL

    researchmap

  • IFN-a,low dose IL-2,UFT併用療法PD後の腎癌に対しnivolumabが奏効した1例

    晝間楓, 結城恵里, 山名一寿, 丸山亮, 冨田善彦

    腎癌研究会会報   ( 48 )   52 - 52   2018

    　More details

    Language：Japanese   Publisher：(一社)腎癌研究会  

    J-GLOBAL

    researchmap

  • 重複腎盂尿管に伴う異所性尿管瘤に対して経尿道的尿管瘤切開術を施行した症例

    小原健司, 星井達彦, 山名一寿, 石崎文雄, 黒木大生, 晝間楓, 結城恵里, 星野さや香, 冨田善彦, 水澤隆樹

    日本泌尿器科学会総会(Web)   106th   2018

    　More details

  • 重複腎盂尿管に伴う異所性尿管瘤に対して経尿道的尿管瘤切開術を施行した症例

    小原健司, 星井達彦, 山名一寿, 石崎文雄, 黒木大生, 晝間楓, 結城恵里, 冨田善彦, 水澤隆樹

    日本小児泌尿器科学会雑誌   27 ( 2 )   OP - 456   2018

    　More details

    Language：Japanese   Publisher：(一社)日本泌尿器科学会総会事務局  

    J-GLOBAL

    researchmap

  • 転移性前立腺癌患者に対するアンドロゲン除去療法後の血中テストステロン値の検討

    晝間楓, 瀧澤逸大, 笠原隆, 原昇, 谷川俊介, 西山勉

    日本泌尿器科学会総会プログラム抄録集(CD-ROM)   103rd   718 - 718   2015

    　More details

    Language：Japanese   Publisher：(一社)日本泌尿器科学会総会事務局  

    J-GLOBAL

    researchmap

  • 転移性前立腺癌における体幹部MRIを用いた転移巣評価について

    瀧澤逸大, 晝間楓, 白野侑子, 笠原隆, 原昇, 谷川俊貴, 麻谷美奈, 西山勉

    日本泌尿器科学会総会プログラム抄録集(CD-ROM)   103rd   656 - 656   2015

    　More details

    Language：Japanese   Publisher：(一社)日本泌尿器科学会総会事務局  

    J-GLOBAL

    researchmap

  • 右趾切断後,左腸骨窩に移植した糖尿病性腎症の1例

    晝間楓, 中川由紀, 池田正博, 田崎正行, 齋藤和英, 小原健司, 谷川俊貴, 成田一衛, 高橋公太

    泌尿器外科   28 ( 臨増 )   830 - 830   2015

    　More details

    Language：Japanese   Publisher：医学図書出版(株)  

    J-GLOBAL

    researchmap

  • 尿管瘤に対して内視鏡的瘤切開を施行した症例

    小原健司, 池田正博, 白野侑子, 晝間楓, 星井達彦, 瀧澤逸大, 冨田善彦, 水澤隆樹

    日本小児泌尿器科学会雑誌   24 ( 2 )   214 - 214   2015

    　More details

    Language：Japanese   Publisher：日本小児泌尿器科学会  

    J-GLOBAL

    researchmap

  • 腎移植後に深部静脈血栓症とクモ膜下出血を発症した脳死下献腎移植の一例

    晝間楓, 中川由紀, 池田正博, 田崎正行, 齋藤和英, 高橋公太

    東北腎不全研究会プログラム・抄録集   41st   2014

    　More details

▶ display all